Tyler Moser, in Castorland, NY - Physical Therapist

Tyler Moser, is a Physical Therapist based in Castorland, New York. Tyler Moser is licensed to practice in New York (license number 036482-1) and his current practice location is 8456 Deveines Rd, Castorland, New York. He can be reached at his office (for appointments etc.) via phone at (315) 221-0750.

NPI number for Tyler Moser is 1245669878 and his current mailing address is 8456 Deveines Rd, Castorland, New York. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1245669878.

Contact Information

	Tyler Moser,
	8456 Deveines Rd, Castorland, NY 13620-1222
	(315) 221-0750
	Not Available

Healthcare Provider's Profile

Full Name	Tyler Moser
Gender	Male
Speciality	Physical Therapist
Location	8456 Deveines Rd, Castorland, New York
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1245669878
Provider Enumeration Date: 11/04/2013
Last Update Date: 11/04/2013

Medical Identifiers

Medical identifiers for Tyler Moser such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1245669878	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225100000X	Physical Therapist	036482-1 (New York)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Tyler Moser is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Tyler Moser, 8456 Deveines Rd, Castorland, NY 13620-1222 Ph: (315) 221-0750	Tyler Moser, 8456 Deveines Rd, Castorland, NY 13620-1222 Ph: (315) 221-0750

News Archive

Discovery may accelerate development of new drugs to treat Huntington's disease

By identifying in spinal fluid how the characteristic mutant proteins of Huntington's disease spread from cell to cell, UC Irvine scientists and colleagues have created a new method to quickly and accurately track the presence and proliferation of these neuron-damaging compounds - a discovery that may accelerate the development of new drugs to treat this incurable disease.

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost. In the study, non-preserved latanoprost was compared to Xalatan (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Researchers at Institut Hospital del Mar d'Investigacions M-diques (IMIM) in Barcelona, in collaboration with the Icahn School of Medicine at Mount Sinai in New York and other U.S. Institutions, have found that intestinal mucus not only acts as a physical barrier against commensal bacteria and dietary antigens, but also prevents the onset of inflammatory reactions against these agents.

Study shows safety, efficacy of cystic fibrosis drug in children between 1 to 2 years of age

Ann & Robert H. Lurie Children's Hospital of Chicago is one of the study sites in the open label Phase 3 study that showed safety and effectiveness of the cystic fibrosis drug Kalydeco (ivacaftor) in children ages 1 to 2 years.

Tyler Moser, - Physical Therapist in Castorland, NY